tooluniverse-disease-research-c2660e — independently scanned and version-tracked by SaferSkills.
SaferSkills independently audited tooluniverse-disease-research-c2660e (Agent Skill) and scored it 100/100 (green). The audit ran 55 deterministic rules across Security, Supply Chain, Maintenance, Transparency, and Community; it found 0 high-severity and 0 lower-severity findings. The full rule-by-rule trace and per-finding evidence are below. Free, methodology-open.
Findings & checks · 0 flagged
Every scanned point with the score it earned and what moved between them.
First recorded scan — no prior version to compare against.
The primary manifest — the file an agent reads to learn what this artifact does.
Generate a comprehensive disease research report with full source citations. The report is created as a markdown file and progressively updated during research.
IMPORTANT: Always use English disease names and search terms in tool calls. Respond in the user's language.
When asked about a disease, query Orphanet/OMIM/DisGeNET FIRST. Don't rely on memory for prevalence, genetics, or treatment — these change over time. When you're not sure about a fact, your first instinct should be to SEARCH for it using tools, not to reason harder from memory.
DO NOT show the search process to the user. Instead:
{disease_name}_research_report.mdWhen synthesizing disease etiology, trace the full pathogenic cascade:
This chain structures the Genetic & Molecular Basis (Section 3) and Biological Pathways (Section 5) sections.
| Dim | Section | Key Tools |
|---|---|---|
| 1 | Identity & Classification | OSL_get_efo_id_by_disease_name, ols_search_efo_terms, ols_get_efo_term, umls_search_concepts, icd_search_codes, snomed_search_concepts |
| 2 | Clinical Presentation | OpenTargets phenotypes, HPO lookup, MedlinePlus |
| 3 | Genetic & Molecular Basis | OpenTargets targets, ClinVar variants, GWAS associations, gnomAD |
| 4 | Treatment Landscape | OpenTargets drugs, clinical trials, GtoPdb |
| 5 | Biological Pathways | Reactome pathways, humanbase_ppi_analysis, GTEx expression, HPA |
| 6 | Epidemiology & Literature | PubMed, OpenAlex, Europe PMC, Semantic Scholar |
| 7 | Similar Diseases | OpenTargets similar entities |
| 8 | Cancer-Specific (if applicable) | CIViC genes/variants/therapies |
| 9 | Pharmacology | GtoPdb targets/interactions/ligands |
| 10 | Drug Safety | OpenTargets warnings, clinical trial AEs, FAERS |
See: tool_usage_details.md for complete tool calls per section.
When the input is messy free text (a sample attribute, a synonym, a tissue/organism label) rather than a clean disease name, use ZOOMA_annotate_text to map it to standardized ontology terms (EFO/MONDO/UBERON/etc.) before lookup. It returns each match as an ontology IRI with a confidence rating (HIGH/GOOD/MEDIUM/LOW), so you can keep only high-confidence hits and feed the resolved ID into OLS / OpenTargets.
tu.run_tool("ZOOMA_annotate_text", {
"property_value": "asthma", # free text to resolve
"property_type": "disease", # optional context hint
"min_confidence": "HIGH", # drop fuzzy matches
"max_results": 3,
})
# -> [{"semantic_tags": ["http://purl.obolibrary.org/obo/MONDO_0004979"],
# "curies": ["MONDO:0004979"], "confidence": "HIGH", "source": "zooma", ...}]
# Restrict to one ontology source (e.g. EFO) when you need a specific namespace:
tu.run_tool("ZOOMA_annotate_text", {"property_value": "diabetes", "ontologies": "efo"})
# Inspect which curated datasources back ZOOMA annotations (for provenance):
tu.run_tool("ZOOMA_list_datasources", {})
# -> [{"name": "eva-clinvar", "type": "DATABASE", "uri": "https://www.ebi.ac.uk/eva"}, ...]Each match also carries a ready-to-use curies field (e.g. MONDO:0004979) so you can feed the resolved ID straight into OLS / OpenTargets without parsing the IRI. ZOOMA is the live replacement for the retired OxO cross-reference service; pair it with ols_get_efo_term to expand the resolved IRI into labels, synonyms, and hierarchy.
Create this file structure at the start:
# Disease Research Report: {Disease Name}
**Report Generated**: {date}
**Disease Identifiers**: (to be filled)
---
## Executive Summary
(Brief 3-5 sentence overview - fill after all research complete)
---
## 1. Disease Identity & Classification
### Ontology Identifiers
| System | ID | Source |
### Synonyms & Alternative Names
### Disease Hierarchy
---
## 2. Clinical Presentation
### Phenotypes (HPO)
| HPO ID | Phenotype | Description | Source |
### Symptoms & Signs
### Diagnostic Criteria
---
## 3. Genetic & Molecular Basis
### Associated Genes
| Gene | Score | Ensembl ID | Evidence | Source |
### GWAS Associations
| SNP | P-value | Odds Ratio | Study | Source |
### Pathogenic Variants (ClinVar)
---
## 4. Treatment Landscape
### Approved Drugs
| Drug | ChEMBL ID | Mechanism | Phase | Target | Source |
### Clinical Trials
| NCT ID | Title | Phase | Status | Source |
---
## 5. Biological Pathways & Mechanisms
## 6. Epidemiology & Risk Factors
## 7. Literature & Research Activity
## 8. Similar Diseases & Comorbidities
## 9. Cancer-Specific Information (if applicable)
## 10. Drug Safety & Adverse Events
---
## References
### Tools Used
| # | Tool | Parameters | Section | Items Retrieved |Every piece of data MUST include its source:
In tables: Add a Source column with tool name In lists: - Finding [Source: tool_name] In prose: (Source: tool_name, query: "...") References section: Complete tool usage log with parameters
# After each dimension's research:
# 1. Read current report
# 2. Replace placeholder with formatted content
# 3. Write back immediately
# 4. Continue to next dimensionEvery finding in the report should be graded:
| Grade | Criteria | Example |
|---|---|---|
| T1 (Strong) | Replicated genetic evidence (GWAS, rare variants), FDA-approved therapy | BRCA1 → breast cancer; trastuzumab for HER2+ |
| T2 (Moderate) | Single genetic study, phase II+ trial data, strong biological evidence | FOXO3 → longevity (centenarian studies) |
| T3 (Association) | Observational data, gene expression changes, pathway membership | IL-6 elevated in Alzheimer's CSF |
| T4 (Computational) | Network proximity, text mining, predicted associations | DisGeNET text-mined gene-disease link |
After collecting data from all 10 dimensions, the report MUST answer:
When multiple databases provide different data for the same disease:
| Conflict | Resolution |
|---|---|
| Different prevalence estimates across sources | Report range; note the most recent/largest study |
| Drug approved in one country but not another | Note regulatory status per region |
| Gene-disease association in one DB but absent in another | Grade by evidence type; text-mining alone is T4 |
| Clinical trial results contradict label indications | The trial result is newer evidence; note both |
For a well-studied disease (e.g., Alzheimer's), the final report should include:
Total: 500+ individual data points, each with source citation.
For rare disease differential diagnosis, run: python3 skills/tooluniverse-rare-disease-diagnosis/scripts/clinical_patterns.py --type differential --symptoms 'symptom1,symptom2'
~30 seconds. Free. No account. Every finding cites a rule and a line of evidence.